Zentalis Pharmaceuticals Announces Fast Track Designation Granted by the U.S. FDA to ZN-c3 for the Treatment of Uterine Serous Carcinoma

Liz Kane
Impactful Strategy

Paul Theisen
Patient Acquisition

Pat Purcell
Meeting Engagement

Matt Turner
Patient Affordability

Bud Bilanich
Success Coach

Frank Burrell
Scientific Storytelling

David Linetsky
Point-of-Care Marketing

Brenda Snow
Authentic Patient Voice

Daniel Sontupe
Market Access

Suma Ramadas, PhD
Medical Affairs

Matthew Durham
Omnidynamic Marketing

Stacey Gandler
Brand Nourishment

Amy Giles
Increasing Engagement

Joey Cohen
Medication Adherence